THE IMPORTANCE OF VISUAL SCREENING FOR LUNG CANCER
Relevance.Lung cancer is the leading cause of death among all cancers. An estimated 29% of the world's population over the age of 15 currently smoke tobacco. The presence of a high-risk population among tobacco smokers, the relatively asymptomatic nature of the disease at an early stage, and a relatively good prognosis with early detection make lung cancer screening attractive. This systematic review discusses recent advances in the use of imaging technologies in lung cancer screening, the rationale for screening, the results of ongoing research, and the current knowledge gaps in lung cancer screening.
Aim. To review well-established imaging techniques, computed tomography and chest radiography, in lung cancer screening.
Search strategy. The study examined full-text publications of foreign studies devoted to the methods of visual diagnostics, computed tomography and survey radiography of the lungs. The following search engines were used in the process of searching for literature: Pubmed, Web of science, Google Scholar by keywords. Publications with a depth of 20 years were studied and analyzed, but some studies of authoritative authors of earlier years were included, which were of great value and without which it would be difficult to present the achievements in this area, the articles were mainly foreign and in English. More than 132 publications were identified on this topic. Of these, 67 publications met the objectives of our study. Inclusion criteria: Publications of evidence level A, B: meta-analyses, systematic reviews, cohort and cross-sectional studies. Exclusion criteria: brief reports, newspaper articles and personal communications.
Results and conclusions. Comparison of plain chest radiography and computed tomography of the lungs in lung cancer screening. Advantages and disadvantages of imaging methods for lung cancer diagnosis are described. Cost-effectiveness of lung cancer screening using computed tomography and plain chest radiography is substantiated. Comparison of various aspects of chest radiography and computed tomography of the lungs in lung cancer screening based on the most advanced and emerging research.
Кузнецова Талина Валерьевна - заведующая отделением лучевой диагностики Центра ядерной медицины и онкологии, ул. Кутжанова, 3, г. Семей, Республика Казахстан; https://orcid.org/0009-0009-0454-6186; e-mail: talina_list@mail.ru; 8-705-281-65-79
Сабирова Альбина Амировна - врач отделения лучевой диагностики Центра ядерной медицины и онкологии, ул. Кутжанова, 3, г. Семей, Республика Казахстан; https://orcid.org/0009-0005-8648-0029; e-mail: bina-semsk@mail.ru; 8-775-623-79-83
Сальжанова Диана Борисовна - врач отделения лучевой диагностики Центра ядерной медицины и онкологии, ул. Кутжанова, 3, г. Семей, Республика Казахстан; https://orcid.org/0009-0006-5515-4463; e-mail: Salzhanova91@mail.ru; 8-707-907-68-17
Дуйсенбаева Бахыт Сержановна. - заведующая отделением диагностической радиологии, клинико-академического отделения радиологии и ядерной медицины Корпоративный фонд «Университетская медицинская школа»; https://orcid.org/0009-0003-3380-0100; e-mail: bakytduisenbayeva@gmail.com; +7-701-782-45-84
Манатова Альмира Манатқызы - PhD, ведущий специалист отдела науки, ТОО «Национальный научный онкологический центр», г. Астана, Республика Казахстан. Тел.: 8 702 880 20 22, e-mail: m.almira@cancercenter.kz, https://orcid.org/0009-0007-6460-5606;
Оразалина Айнаш Сапаровна – кандидат биологических наук, доцент, заведующая кафедрой молекулярной биологии и медицинской генетики имени академика НАН РК Т.К. Раисова, НАО «Медицинский университет Семей», ул. Абая, 103, г. Семей, Республика Казахстан; https://orcid.org/0000-0003-4594-0138; e-mail:ainash.orazalina@smu.edu.kz; +7-777-235-47-72
Ван Ольга Толеубековна – преподаватель кафедры симуляционных и образовательных технологий, НАО «Медицинский университет Семей», ул. Абая, 103, г. Семей, Республика Казахстан; https://orcid.org/0000-0003-3065-2061; e-mail:olga.van@smu.edu.kz; 7-771-540-86-17
Сыздыкбаев Марат Келисович - доктор медицинских наук, профессор кафедры госпитальной хирургии, анестезиологии и реаниматологии НАО «Медицинский университет Семей», ул. Абая, 103, г. Семей, Республика Казахстан; https://orcid.org/0000-0002-0561-4111; e-mail: marat.syzdykbayev@smu.edu.kz; +7-777-633-47-57
1. Aberle D.R., Adams A.M., Berg C.D., Black W.C., Clapp J.D., Fagerstrom R.M., Gareen I.F., Gatsonis C., Marcus P.M., Sicks J.D. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011. T. 365, № 5. C. 395-409.
2. Bach P.B., Mirkin J.N., Oliver T.K., Azzoli C.G., Berry D.A., Brawley O.W., Byers T., Colditz G.A., Gould M.K., Jett J.R., Sabichi A.L., Smith-Bindman R., Wood D.E., Qaseem A., Detterbeck F.C. Benefits and harms of CT screening for lung cancer: a systematic review. Jama. 2012. T. 307, № 22. C. 2418-29.
3. Baldwin D.R., Duffy S.W., Wald N.J., Page R., Hansell D.M., Field J.K. UK Lung Screen (UKLS) nodule management protocol: modelling of a single screen randomised controlled trial of low-dose CT screening for lung cancer. Thorax. 2011. T. 66, № 4. C. 308-13.
4. Becker N., Motsch E., Gross M.L., Eigentopf A., Heussel C.P., Dienemann H., Schnabel P.A., Pilz L., Eichinger M., Optazaite D.E., Puderbach M., Tremper J., Delorme S. Randomized study on early detection of lung cancer with MSCT in Germany: study design and results of the first screening round. J Cancer Res Clin Oncol. 2012. T. 138, № 9. C. 1475-86.
5. Becker N., Motsch E., Trotter A., Heussel C.P., Dienemann H., Schnabel P.A., Kauczor H.U., Maldonado S.G., Miller A. B., Kaaks R., Delorme S. Lung cancer mortality reduction by LDCT screening-Results from the randomized German LUSI trial. Int J Cancer. 2020. T. 146, № 6. C. 1503-1513.
6. Black C., Bagust A., Boland A., Walker S., McLeod C., De Verteuil R., Ayres J., Bain L., Thomas S., Godden D., Waugh N. The clinical effectiveness and cost-effectiveness of computed tomography screening for lung cancer: systematic reviews. Health Technol Assess. 2006. T. 10, № 3. C. 1-90.
7. Black W.C. Unexpected observations on tumor size and survival in stage IA non-small cell lung cancer. Chest. 2000. T. 117, № 6. C. 1532-4.
8. Black W.C., Gareen I.F., Soneji S.S., Sicks J.D., Keeler E.B., Aberle D.R., Naeim A., Church T.R., Silvestri G.A., Gorelick J., Gatsonis C. Cost-effectiveness of CT screening in the National Lung Screening Trial. N Engl J Med. 2014. T. 371, № 19. C. 1793-802.
9. Blanchon T., Bréchot J.M., Grenier P.A., Ferretti G.R., Lemarié E., Milleron B., Chagué D., Laurent F., Martinet Y., Beigelman-Aubry C., et al.Baseline results of the Depiscan study: a French randomized pilot trial of lung cancer screening comparing low dose CT scan (LDCT) and chest X-ray (CXR). Lung Cancer. 2007. T. 58, № 1. C. 50-8.
10. Brenner D.J. Radiation risks potentially associated with low-dose CT screening of adult smokers for lung cancer. Radiology. 2004. T. 231, № 2. C. 440-5.
11. Chaudhry A., Gul M., Chaudhry A. Utility of computed tomography lung cancer screening and the management of computed tomography screen-detected findings. J Thorac Dis. 2018. T. 10, № 3. C. 1352-1355.
12. Chung M., Tam K., Wallace C., Yip R., Yankelevitz D.F., Henschke C. I., Investigators I.-E. International Early Lung Cancer Action Program: update on lung cancer screening and the management of CT screen-detected finding. AME Medical Journal. 2017. T. 2, № 8. рр.984-971
13. Clark K.W., Gierada D.S., Marquez G., Moore S.M., Maffitt D.R., Moulton J. D., Wolfsberger M.A., Koppel P., Phillips S.R., Prior F.W. Collecting 48,000 CT exams for the lung screening study of the National Lung Screening Trial. Journal of digital imaging. 2009. T. 22. C. 667-680.
14. Statistical power analysis for the behavioral sciences. Cohen J.: Academic press, 2013. рр.98-105
15. Croswell J.M., Baker S.G., Marcus P.M., Clapp J. D., Kramer B.S. Cumulative incidence of false-positive test results in lung cancer screening: a randomized trial. Ann Intern Med. 2010. T. 152, № 8. C. 505-12, w176-80.
16. de Koning H.J., van der Aalst C.M., de Jong P.A., Scholten E.T., Nackaerts K., Heuvelmans M.A., Lammers J.J., Weenink C., Yousaf-Khan U., Horeweg N., van 't Westeinde S., et al. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. N Engl J Med. 2020. T. 382, № 6. C. 503-513.
17.Drummond M.F., Sculpher M.J., Claxton K., Stoddart G.L., Torrance G.W.Methods for the economic evaluation of health care programmes. Oxford university press, 2015.
18. Ettinger D.S., Wood D.E., Akerley W., Bazhenova L.A., Borghaei H., Camidge D.R., Cheney R.T., Chirieac L.R., D'Amico T.A., et al. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. J Natl Compr Canc Netw. 2016. T. 14, № 3. C. 255-64.
19. Fontana R.S., Sanderson D.R., Woolner L.B., Taylor W.F., Miller W.E., Muhm J.R. Lung cancer screening: the Mayo program. J Occup Med. 1986. T. 28, № 8. C. 746-50.
20. Gohagan J.K., Marcus P.M., Fagerstrom R.M., Pinsky P.F., Kramer B.S., Prorok P.C., Ascher S., Bailey W., Brewer B., Church T. Final results of the Lung Screening Study, a randomized feasibility study of spiral CT versus chest X-ray screening for lung cancer. Lung cancer. 2005. T. 47, № 1. C. 9-15.
21. Gohagan J.K., Brewer B., Church T., Kramer B.S., Marcus P.M. et al. Preliminary results of a study of helical CT versus chest x-ray for lung cancer screening. Lung Cancer. 2003. T. 45, № 4. C. 25-32.
22. Goldstraw P., Crowley J., Chansky K., Giroux D.J., Groome P.A., Rami-Porta R., Postmus P.E., Rusch V., Sobin L. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007. T. 2, № 8. C. 706-14.
23. Gopal M., Abdullah S.E., Grady J.J., Goodwin J.S. Screening for lung cancer with low-dose computed tomography: a systematic review and meta-analysis of the baseline findings of randomized controlled trials. J Thorac Oncol. 2010. T. 5, № 8. C. 1233-9.
24. Henschke C.I. Early lung cancer action project: overall design and findings from baseline screening. Cancer. 2000. . 89, № S11. C. 2474-2482.
25. Henschke C.I., McCauley D., Yankelevitz D.F., Naidich D.P., McGuinness G., Miettinen O.S., Libby D.M., Pasmantier M.W., Koizumi J., Altorki N.K. Early Lung Cancer Action Project: overall design and findings from baseline screening. The Lancet. 1999.T. 354, № 9173. C. 99-105.
26. Henschke C.I., McCauley D.I., Yankelevitz D.F., Naidich D.P., McGuinness G., Miettinen O.S., Libby D.M., Pasmantier M.W., Koizumi J., Altorki N.K., Smith J.P. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet. 1999. nT. 354, № 9173. C. 99-105.
27. Higgins J.P., Li T., Deeks J.J. Choosing effect measures and computing estimates of effect. Cochrane handbook for systematic reviews of interventions. 2019. C. 143-176.
28. Iinuma T., Tateno Y., Matsumoto T., Yamamoto S., Matsumoto M. Preliminary specification of X-ray CT for lung cancer screening (LSCT) and its evaluation on risk-cost-effectiveness. Nihon Igaku Hoshasen Gakkai zasshi. Nippon Acta Radiologica. 1992. T. 52, № 2. C. 182-190.
29. Infante M., Cavuto S., Lutman F. R., Brambilla G., Chiesa G., Ceresoli G., Passera E., Angeli E., Chiarenza M., Aranzulla G., Cariboni U., Errico V., Inzirillo F., Bottoni E., Voulaz E., Alloisio M., Destro A., Roncalli M., Santoro A., Ravasi G. A randomized study of lung cancer screening with spiral computed tomography: three-year results from the DANTE trial. Am J Respir Crit Care Med. 2009. T. 180, № 5. C. 445-53.
30. Jaklitsch M.T., Jacobson F.L., Austin J.H., Field J.K., Jett J.R., Keshavjee S., MacMahon H., Mulshine J.L., Munden R.F., Salgia R., Strauss G.M., Swanson S.J., Travis W.D., Sugarbaker D. J. The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. J Thorac Cardiovasc Surg. 2012. T. 144, № 1. C. 33-8.
31. Kazerooni E.A., Armstrong M.R., Amorosa J. ., Hernandez D., Liebscher L.A., Nath H., McNitt-Gray M.F., Stern E.J., Wilcox P. A. ACR CT accreditation program and the lung cancer screening program designation. J Am Coll Radiol. 2015. T. 12, № 1. C. 38-42.
32. Krist A.H., Davidson K.W., Mangione C.M., Barry M.J., Cabana M., Caughey A. B., Davis E.M., Donahue K. E., Doubeni C. A., Kubik M. Screening for lung cancer: US Preventive Services Task Force recommendation statement. Jama. 2021. T. 325, № 10. C. 962-970.
33. Lopes Pegna A., Picozzi G., Mascalchi M., Maria Carozzi F., Carrozzi L., Comin C., Spinelli C., Falaschi F., Grazzini M., Innocenti F., Ronchi C., Paci E. Design, recruitment and baseline results of the ITALUNG trial for lung cancer screening with low-dose CT. Lung Cancer. 2009. T. 64, № 1. C. 34-40.
34. MacMahon H., Naidich D.P., Goo J.M., Lee K.S., Leung A.N.C., Mayo J.R., Mehta A.C., Ohno Y., Powell C.A., Prokop M., Rubin G.D., Schaefer-Prokop C.M., Travis W.D., Van Schil P.E., Bankier A.A. Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017. Radiology. 2017. T. 284, № 1. C. 228-243.
35. Mahadevia P.J., Fleisher L.A., Frick K.D., Eng J., Goodman S.N., Powe N.R. Lung cancer screening with helical computed tomography in older adult smokers: a decision and cost-effectiveness analysis. Jama. 2003. T. 289, № 3. C. 313-22.
36. Manser R., Dalton A., Carter R., Byrnes G., Elwood M., Campbell D.A. Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting. Lung Cancer. 2005. T. 48, № 2. C. 171-85.
37. Manser R.L., Irving L.B., Stone C., Byrnes G., Abramson M., Campbell D. Screening for lung cancer. Cochrane Database Syst Rev. 2004.10.1002/14651858.CD001991.pub2 № 1. C. Cd001991.
38. Marshall D., Simpson K.N., Earle C.C., Chu C.W. Economic decision analysis model of screening for lung cancer. Eur J Cancer. 2001. T. 37, № 14. C. 1759-67.
39. Matsumoto M., Horikoshi H., Moteki T., Hatori N., Tateno Y., Iinuma T., Matsumoto T., Yamamoto S., Baba T. A pilot study with lung-cancer screening CT (LSCT) at the secondary screening for lung cancer detection. Nihon Igaku Hoshasen Gakkai zasshi. Nippon Acta Radiologica. 1995. T. 55, № 3. C. 172-179.
40. McWilliams A., Tammemagi M.C., Mayo J.R., Roberts H., Liu G., Soghrati K., Yasufuku K., Martel S., Laberge F., Gingras M., et al.Probability of cancer in pulmonary nodules detected on first screening CT. N Engl J Med. 2013. T. 369, № 10. C. 910-9.
41. Melamed M.R., Flehinger B.J., Zaman M.B., Heelan R.T., Perchick W.A., Martini N. Screening for early lung cancer. Results of the Memorial Sloan-Kettering study in New York. Chest. 1984. T. 86, № 1. C. 44-53.
42. Moher D., Liberati A., Tetzlaff J., Altman D. G., Group* P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Annals of internal medicine. 2009. T. 151, № 4. C. 264-269.
43. Moyer V.A., Force U.P. Screening for lung cancer: US Preventive Services Task Force recommendation statement. Annals of internal medicine. 2014. T. 160, № 5. C. 330-338.
44. Oken M.M., Hocking W.G., Kvale P.A., Andriole G.L., Buys S.S., Church T.R., Crawford E.D., Fouad M.N., Isaacs C., Reding D.J., Weissfeld J.L., Yokochi L.A., et al. Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. Jama. 2011. T. 306, № 17. C. 1865-73.
45. Paci E., Puliti D., Pegna A. L., Carrozzi L., Picozzi G., Falaschi F., Pistelli F., Aquilini F., Ocello C., Zappa M. Mortality, survival and incidence rates in the ITALUNG randomised lung cancer screening trial. Thorax. 2017. T. 72, № 9. C. 825-831.
46. Parker V.L., Winter M.C., Whitby E., Parker W.A. E., Palmer J.E., Tidy J.A., Pacey A.A., Hancock B.W., Harrison R.F. Computed tomography chest imaging offers no advantage over chest X-ray in the initial assessment of gestational trophoblastic neoplasia. Br J Cancer. 2021. T. 124, № 6. C. 1066-1071.
47. Passiglia F., Bertolaccini L., Del Re M., Facchinetti F., Ferrara R., Franchina T., Malapelle U., Menis J., Passaro A., Pilotto S., Ramella S., Rossi G., Trisolini R., Novello S. Diagnosis and treatment of early and locally advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines. Crit Rev Oncol Hematol. 2020. T. 148. C. 102862.
48. Passiglia F., Cinquini M., Bertolaccini L., Del Re M., Facchinetti F., Ferrara R., Franchina T., Larici A. R., Malapelle U., Menis J., Passaro A., Pilotto S., Ramella S., Rossi G., Trisolini R., Novello S. Benefits and Harms of Lung Cancer Screening by Chest Computed Tomography: A Systematic Review and Meta-Analysis. J Clin Oncol. 2021. T. 39, № 23. C. 2574-2585.
49. Passiglia F., Pilotto S., Facchinetti F., Bertolaccini L., Del Re M., Ferrara R., Franchina T., Malapelle U., Menis J., Passaro A., Ramella S., Rossi G., Trisolini R., Novello S. Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines. Crit Rev Oncol Hematol. 2020. T. 146. C. 102858.
50. Pastorino U., Rossi M., Rosato V., Marchianò A., Sverzellati N., Morosi C., Fabbri A., Galeone C., Negri E., Sozzi G., Pelosi G., La Vecchia C. Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial. Eur J Cancer Prev. 2012. T. 21, № 3. C. 308-15.
51. Pastorino U., Silva M., Sestini S., Sabia F., Boeri M., Cantarutti A., Sverzellati N., Sozzi G., Corrao G., Marchianò A. Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy. Ann Oncol. 2019. T.30, № 7. C. 1162-1169.
52. Pedersen J.H., Ashraf H., Dirksen A., Bach K., Hansen H., Toennesen P., Thorsen H., Brodersen J., Skov B.G., Døssing M., Mortensen J., Richter K., Clementsen P., Seersholm N. The Danish randomized lung cancer CT screening trial-overall design and results of the prevalence round. J Thorac Oncol. 2009. T. 4, № 5. C. 608-14.
53. Raymakers A.J., Mayo J., Lam S., FitzGerald J.M., Whitehurst D.G., Lynd L.D. Cost-Effectiveness Analyses of Lung Cancer Screening Strategies Using Low-Dose Computed Tomography: a Systematic Review. Appl Health Econ Health Policy. 2016. T. 14, № 4. C. 409-418.
54. Ries L., Melbert D., Krapcho M., Stinchcomb D., Howlader N., Horner M., Mariotto A., Miller B., Feuer E., Altekruse S. SEER cancer statistics review, 1975–2005. Bethesda, MD: National Cancer Institute. 2008. T. 2999.
55. Sanchez-Salcedo P., Wilson D.O., de-Torres J.P., Weissfeld J.L., Berto J., Campo A., Alcaide A. B., Pueyo J., Bastarrika G., Seijo L.M., Pajares M.J., Pio R., Montuenga L.M., Zulueta J.J. Improving selection criteria for lung cancer screening. The potential role of emphysema. Am J Respir Crit Care Med. 2015. T. 191, № 8. C. 924-31.
56. Sankaranarayanan R., Swaminathan R., Brenner H., Chen K., Chia K.S., Chen J.G., Law S.C., Ahn Y.O., Xiang Y.B., Yeole B.B., Shin H.R., Shanta V., Woo Z.H., Martin N., Sumitsawan Y., Sriplung H., Barboza A.O., Eser S., Nene B.M., Suwanrungruang K., Jayalekshmi P., Dikshit R., Wabinga H., Esteban D.B., Laudico A., Bhurgri Y., Bah E., Al-Hamdan N. Cancer survival in Africa, Asia, and Central America: a population-based study. Lancet Oncol. 2010. T. 11, № 2. C. 165-73.
57. Sant M., Allemani C., Santaquilani M., Knijn A., Marchesi F., Capocaccia R. EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer. 2009. T. 45, № 6. C. 931-91.
58. Schünemann H.J. Using Systematic Reviews in Guideline Development: The GRADE Approach. Systematic Reviews in Health Research: Meta‐Analysis in Context. 2022. C. 424-448.
59. Schünemann H.J., Oxman A.D., Higgins J.P., Vist G.E., Glasziou P., Guyatt G.H. Presenting results and ‘Summary of findings’ tables. Cochrane handbook for systematic reviews of interventions: Cochrane book series. 2008. C. 335-357.
60. Scott W.J., Howington J., Feigenberg S., Movsas B., Pisters K. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007. T. 132, № 3 Suppl. C. 234s-242s.
61. Takemura T., Sakai E., Kusumoto M., Itoji E., Adachi S., Kono M. Utility of helical CT for the secondary mass screening of lung cancer. Nihon Igaku Hoshasen Gakkai zasshi. Nippon Acta Radiologica. 1992. T. 52, № 9. C. 1322-1324.
62. van Beek E.J., Mirsadraee S., Murchison J.T. Lung cancer screening: Computed tomography or chest radiographs? World J Radiol. 2015. T. 7, № 8. C. 189-93.
63. van den Bergh K.A., Essink-Bot M.L., Bunge E.M., Scholten E.T., Prokop M., van Iersel C.A., van Klaveren R.J., de Koning H.J. Impact of computed tomography screening for lung cancer on participants in a randomized controlled trial (NELSON trial). Cancer. 2008. T. 113, № 2. C. 396-404.
64. van Iersel C.A., de Koning H.J., Draisma G., Mali W.P., Scholten E.T., Nackaerts K., Prokop M., Habbema J.D., Oudkerk M., van Klaveren R.J. Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). Int J Cancer. 2007. T. 120, № 4. C. 868-74.
65. Villanti A. C., Jiang Y., Abrams D. B., Pyenson B. S. A cost-utility analysis of lung cancer screening and the additional benefits of incorporating smoking cessation interventions. PLoS One. 2013. T. 8, № 8. C. e71379.
66. Wood D.E., Eapen G.A., Ettinger D.S., Hou L., Jackman D., Kazerooni E., Klippenstein D., Lackner R.P., Leard L., Leung A.N., Massion P.P., Meyers B.F., Munden R.F., Otterson G.A., Peairs K., Pipavath S., Pratt-Pozo C., Reddy C., Reid M.E., Rotter A.J., Schabath M.B., Sequist L.V., Tong B.C., Travis W.D., Unger M., Yang S.C. Lung cancer screening. J Natl Compr Canc Netw. 2012. T. 10, № 2. C. 240-65.
67. Yip R., Yankelevitz D.F., Hu M., Li K., Xu D.M., Jirapatnakul A., Henschke C.I. Lung Cancer Deaths in the National Lung Screening Trial Attributed to Nonsolid Nodules. Radiology. 2016. T. 281, № 2. C. 589-596.
Number of Views: 19
Category of articles:
Reviews
Bibliography link
Kuznetsova T.V., Sabirova A.A., Salzhanova D.B., Duisenbayeva B.S., Manatova A.M., Orazalina A.S., Van O.T., Syzdykbayev M.K. The importance of visual screening for lung cancer // Nauka i Zdravookhranenie [Science & Healthcare]. 2024. Vol.26 (6), pp. 152-163. doi 10.34689/SH.2024.26.6.018Related publications:
CURRENT STATE OF DERMATOPHYTE RESISTANCE TO ANTIMYCOTIC AGENTS
THE ROLE OF BIOMEDICAL INFORMATICS IN THE STUDY OF BRONCHOPULMONARY DYSPLASIA
THE IMPORTANCE OF VISUAL SCREENING FOR LUNG CANCER
DIAGNOSIS AND TREATMENT OF KIDNEY TRANSPLANT REJECTION: A LITERATURE REVIEW.
COMPARATIVE CHARACTERISTICS OF BREAST RECONSTRUCTION METHODS. LITERATURE REVIEW